Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (252)	11/27/2002 9:40:28 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 469

more deep stuff from Progen...... International Oncology Experts Meet in Brisbane To Discuss Progen's PI-88 Wednesday November 27, 9:30 am ET BRISBANE, Australia--(BUSINESS WIRE)--Nov. 27, 2002--Progen Industries (ASX:PGL - News), (Nasdaq:PGLAF - News) Clinical oncology experts from the USA, Taiwan and Australia conducting PI-88 clinical trials convened this week with Progen researchers in Brisbane. The purpose of the meeting was to share clinical experiences, discuss Progen's PI-88 clinical data and look ahead to the future clinical program. Assistant Professor Scott Holden, a clinical investigator with Progen's Phase I/II melanoma trial in Denver, Colorado commented, "It was a productive meeting, giving us a clear picture of the clinical behavior of PI-88 across all trials. This is critical in helping us to better understand the product and determine the best method to uncover and exploit PI-88's utility as a cancer agent." Dr. Robert Don, Progen's VP of R&D added; "Following Monday's announcement of encouraging preliminary results on PI-88 at the European Organisation for Research and Treatment of Cancer (EORTC) meeting, it was gratifying to see international experts discussing their accumulated experiences and data and debating different ways to ensure that the clinical program and potential of PI-88 is optimised." PI-88 is a semi-synthetic sulphated oligosaccharide that has several modes of action. In animal models it has been shown to block tumour growth by preventing angiogenesis by inhibiting fibroblast growth factor. It has also been shown to block the spread of cancer (metastasis) by inhibiting the enzyme heparanase, which allows cancer cells to escape blood vessels. Finally, PI-88 stimulates sustained release of a molecule known as TFPI (or tissue factor pathway inhibitor) from cells lining the blood vessel wall. TFPI is one of the body's natural inhibitors of new blood vessel growth. Progen Industries Limited (www.progen.com.au) is a Brisbane-based, internationally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals: potent, selective inhibitors of carbohydrate-protein interactions implicated in a range of human illnesses. The company's lead drug candidate, PI-88, is under development as a potential treatment for cancer. Progen also operates two commercial business arms, a GMP certified pilot manufacturing facility that provides Contract Services for 3rd party drug manufacturing development and scale-up for early stage clinical trials, and a domestic distribution franchise for major international Life Sciences companies. (snip)